Capital Planning LLC Purchases 183 Shares of Johnson & Johnson (NYSE:JNJ)

Capital Planning LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 13.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,528 shares of the company’s stock after acquiring an additional 183 shares during the period. Capital Planning LLC’s holdings in Johnson & Johnson were worth $221,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Pacer Advisors Inc. increased its holdings in Johnson & Johnson by 15.3% during the 2nd quarter. Pacer Advisors Inc. now owns 240,605 shares of the company’s stock worth $35,167,000 after purchasing an additional 31,908 shares in the last quarter. Sei Investments Co. grew its holdings in Johnson & Johnson by 10.7% during the second quarter. Sei Investments Co. now owns 1,126,658 shares of the company’s stock worth $164,672,000 after buying an additional 109,205 shares in the last quarter. Thrivent Financial for Lutherans raised its position in Johnson & Johnson by 31.8% in the 2nd quarter. Thrivent Financial for Lutherans now owns 1,634,863 shares of the company’s stock valued at $238,951,000 after buying an additional 394,518 shares during the last quarter. Kiely Wealth Advisory Group Inc. boosted its holdings in Johnson & Johnson by 5.7% during the 2nd quarter. Kiely Wealth Advisory Group Inc. now owns 1,847 shares of the company’s stock worth $296,000 after acquiring an additional 99 shares during the last quarter. Finally, Summit Trail Advisors LLC grew its stake in shares of Johnson & Johnson by 30.7% in the 2nd quarter. Summit Trail Advisors LLC now owns 45,920 shares of the company’s stock worth $6,712,000 after acquiring an additional 10,789 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on JNJ shares. Bank of America cut their price target on shares of Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating on the stock in a report on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Morgan Stanley lifted their price target on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Royal Bank of Canada lifted their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Finally, Wells Fargo & Company raised their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $174.29.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $147.03 on Friday. The firm has a market capitalization of $353.99 billion, a P/E ratio of 21.28, a PEG ratio of 2.30 and a beta of 0.51. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The business has a fifty day moving average price of $148.51 and a 200-day moving average price of $155.96.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.37%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.